StockData
Xencor Inc logo

Xencor Inc (XNCR) company profile

XNCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30194% above fair value
$34.39−0.11 (-0.32%)

Close on Nov 18, 2026Market cap $2.56BP/E –Yield –

About Xencor

Pharmaceutical Preparations, SIC 2834

The company is a clinical-stage biopharmaceutical firm focused on discovering and developing engineered antibody therapeutics for patients with cancer and autoimmune diseases. It leverages proprietary protein engineering technologies to design modular Fc domains and multi-specific antibody formats under the XmAb platform, which feature improved half-life, cytotoxic activity, and targeted immune mechanisms. Its pipeline includes wholly owned clinical-stage candidates such as XmAb819 and XmAb541 for oncology indications, and XmAb942, plamotamab, and XmAb657 for autoimmune and inflammatory conditions. The company targets patients with serious unmet medical needs and serves commercial biopharmaceutical partners through collaborative research, product licensing, and platform technology access agreements.

The organization conducts clinical trial programs across Phase 1 and Phase 2 stages and advances partnered candidates through licensing alliances with global reach. Partnered programs utilizing its proprietary technology have produced three commercialized medicines marketed internationally, along with multiple candidates in Phase 2 and Phase 3 development worldwide. The provided text does not disclose the company's founding year, website address, or headquarters location.

Summary of the business section of Xencor's latest annual report, written by StockData.

Company profile

Company

Legal name
Xencor Inc
Headquarters
Pasadena, CA
Address
465 N. Halstead St., Suite 200 91107
Phone
(626) 305-5900
Website
xencor.com
Employees
260, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, San Diego, California

Stock & identifiers

Ticker
XNCR
Exchange
Nasdaq
IPO date
Dec 3, 2013
Shares outstanding
74M, Jul 31, 2026
Public float
$555.94M, Jun 30, 2025
Filer category
Accelerated filer
SEC CIK
1326732
CUSIP
98401F105
ISIN
US98401F1057
FIGI
BBG0026ZG4W0
Share class FIGI
BBG0026ZG4X9
LEI
549300V5IF65437JKG30
EIN
20-1622502

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Bassil I. DahiyatPRESIDENT & CEO, Director546,316
Bart Jan CornelissenSR. VICE PRESIDENT & CFO65,798
John R. DesjarlaisSR. VICE PRESIDENT & CSO263,831
Celia EckertSVP, GENERAL COUNSEL76,918
Nancy ValenteEVP, Chief Development Officer49,169
Richard J. RanieriDirector18,514
Todd E. SimpsonDirector23,988
Ellen FeigalDirector22,642
Alan Bruce MontgomeryDirector25,849
Kurt A. GustafsonDirector25,011
Raymond Joseph DeshaiesDirector10,302
Barbara KlenckeDirector29,974
Kevin Charles GormanDirector21,680

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$5.52M$1.49M$1.39M$35$120
FY2024$6.81M$2.56M$3.14M$53$91
FY2023$7.97M$6.15M$3.12M$49$92
FY2022$7.71M-$770.56K$2.44M$60$89
FY2021$5.37M$317.34K$2.13M$92$99
FY2020$4.48M$6.73M$1.26M$127$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer and Director
$742.80K$1.55M$2.73M$490.25K$8.25K$5.52M-19%
Bart Jan Cornelissen
Chief Financial Officer
$491.60K$310.58K$515.71K$243.34K$81.16K$1.64M-56%
John R. Desjarlais, Ph.D.
Chief Scientific Officer
$547.90K$422.39K$701.37K$301.35K$9.25K$1.98M-30%
Celia E. Eckert
General Counsel
$491.60K$310.58K$515.71K$243.34K$9.25K$1.57M-20%
Nancy K. Valente, M.D.
Former Chief Development Officer
$249.42K–––$181.35K$430.77K-85%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 3, 2013
Securities offered
12,730,000
Exchange
Nasdaq
First trading day
Dec 3, 2013
First-day close
$8.34
Lock-up ends (est.)
Jun 1, 2014

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 260 full-time employees, of which 212 were engaged in research and development activities, and 48 were engaged in business development, information systems, facilities, human resources, or administrative support.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?